Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer

[1] Howard FM(2021)Epidemiology of triple-negative breast cancer: a review Cancer J 27 8-16

[2] Olopade OI(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434

[3] Dent R(2020)Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 21 44-59

[4] Trudeau M(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 396 1817-1828

[5] Pritchard KI(2020)Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma Mod Pathol 33 2221-575

[6] Schmid P(2023)Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer Br J Cancer 128 568-313

[7] Rugo HS(2020)Concordance of programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer J Breast Cancer 23 303-1016

[8] Adams S(2021)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 Study J Natl Cancer Inst 113 1005-684

[9] Cortes J(2023)Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis JCO Precis Oncol 7 e2200317-297

[10] Cescon DW(2020)The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice J Pathol 250 667-170

[1] Howard FM(2021)Epidemiology of triple-negative breast cancer: a review Cancer J 27 8-16

[2] Olopade OI(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434

[3] Dent R(2020)Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 21 44-59

[4] Trudeau M(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 396 1817-1828

[5] Pritchard KI(2020)Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma Mod Pathol 33 2221-575

[6] Schmid P(2023)Impact of adjuvant chemotherapy and radiotherapy on tumour-infiltrating lymphocytes and PD-L1 expression in metastatic breast cancer Br J Cancer 128 568-313

[7] Rugo HS(2020)Concordance of programmed death-ligand 1 expression between SP142 and 22C3/SP263 assays in triple-negative breast cancer J Breast Cancer 23 303-1016

[8] Adams S(2021)Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer: biomarker evaluation of the IMpassion130 Study J Natl Cancer Inst 113 1005-684

[9] Cortes J(2023)Association between biomarkers and clinical outcomes of pembrolizumab monotherapy in patients with metastatic triple-negative breast cancer: KEYNOTE-086 exploratory analysis JCO Precis Oncol 7 e2200317-297

[10] Cescon DW(2020)The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice J Pathol 250 667-170